PD-L1 Cancer Research Results

PD-L1, Programmed Death-Ligand 1: Click to Expand ⟱
Source:
Type:
PD-L1 is a protein that plays a crucial role in the regulation of the immune system. PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection.
PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers.
Cerv, Cervical Cancer: Click to Expand ⟱
Cervical Cancer
Scientific Papers found: Click to Expand⟱
8212- LCA,    Licochalcone A inhibits proliferation and promotes apoptosis of colon cancer cell by targeting programmed cell death-ligand 1 via the NF-κB and Ras/Raf/MEK pathways
- in-vitro, Colon, HepG3 - in-vitro, Lung, A549 - in-vitro, Cerv, HeLa - vitro+vivo, CRC, HCT116
PD-L1↓, p65↓, RAS?, NF-kB↓, T-Cell↑, p‑MEK↓, p‑Raf↓,
8159- UsA,    Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD-L1 expression and enhancing T-lymphocyte tumor-killing activity
- in-vitro, Cerv, HeLa
STAT3↓, RAS↓, mTOR↓, PD-L1↓, TumCP↓, angioG↓, TumCMig↓, TumCI↓, TumCG↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

p‑MEK↓, 1,   p‑Raf↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↓, 1,   RAS?, 1,   RAS↓, 1,   STAT3↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NF-kB↓, 1,   p65↓, 1,   PD-L1↓, 2,   T-Cell↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

PD-L1↓, 2,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PD-L1, Programmed Death-Ligand 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:29  Cells:%  prod#:%  Target#:243  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page